Portola Pharmaceuticals (NASDAQ:PTLA) EVP Tao Fu sold 1,135 shares of the business’s stock in a transaction on Monday, March 12th. The shares were sold at an average price of $38.47, for a total transaction of $43,663.45. Following the sale, the executive vice president now owns 18,346 shares of the company’s stock, valued at approximately $705,770.62. The sale was disclosed in a legal filing with the SEC, which is available at this link.
PTLA stock traded down $1.29 on Friday, reaching $30.91. The company’s stock had a trading volume of 706,040 shares, compared to its average volume of 1,248,273. The company has a quick ratio of 5.92, a current ratio of 5.94 and a debt-to-equity ratio of 0.30. The firm has a market capitalization of $2,105.63, a price-to-earnings ratio of -6.43 and a beta of 1.49. Portola Pharmaceuticals has a 12-month low of $30.10 and a 12-month high of $67.10.
Portola Pharmaceuticals (NASDAQ:PTLA) last announced its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($1.41) EPS for the quarter, beating the consensus estimate of ($1.46) by $0.05. The business had revenue of $9.80 million during the quarter, compared to analyst estimates of $3.71 million. Portola Pharmaceuticals had a negative return on equity of 108.43% and a negative net margin of 1,268.34%. The company’s revenue for the quarter was down 28.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.95) earnings per share. equities research analysts anticipate that Portola Pharmaceuticals will post -4.74 earnings per share for the current year.
Several research firms have commented on PTLA. Zacks Investment Research raised shares of Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday. ValuEngine raised shares of Portola Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, April 2nd. Oppenheimer reissued a “buy” rating on shares of Portola Pharmaceuticals in a report on Wednesday, March 21st. BidaskClub downgraded shares of Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 21st. Finally, William Blair reaffirmed a “buy” rating on shares of Portola Pharmaceuticals in a research note on Tuesday, March 13th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $67.14.
Several institutional investors and hedge funds have recently bought and sold shares of PTLA. Oppenheimer Asset Management Inc. raised its position in shares of Portola Pharmaceuticals by 251.2% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 2,862 shares of the biopharmaceutical company’s stock worth $155,000 after purchasing an additional 2,047 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Portola Pharmaceuticals by 54.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,219 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 1,141 shares during the period. Canada Pension Plan Investment Board bought a new stake in shares of Portola Pharmaceuticals during the 3rd quarter valued at about $178,000. Penbrook Management LLC bought a new stake in shares of Portola Pharmaceuticals during the 4th quarter valued at about $209,000. Finally, Sei Investments Co. bought a new stake in shares of Portola Pharmaceuticals during the 3rd quarter valued at about $217,000. 88.44% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “Portola Pharmaceuticals (PTLA) EVP Sells $43,663.45 in Stock” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/08/tao-fu-sells-1135-shares-of-portola-pharmaceuticals-inc-ptla-stock.html.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily Factor Xa inhibitor for hospital and extended duration prophylaxis of venous thromboembolism in adults hospitalized for an acute medical illness; Andexanet alfa, a recombinant protein that is in Phase III study for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, a spleen tyrosine kinase inhibitor, which is in Phase IIa clinical stage to treat hematologic cancers.
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.